|
Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. Journal of the National Cancer Institute 2012 Dec 5; 104(23):1785-95. [Epub 2012 Nov 28]
Full text
|
|
Betsou F, Gunter E, Clements J, Desouza Y, Goddard KA, Guadagni F, Yan W, Skubitz A, Somiari S, Yeadon T, Chuaqui R. Identification of evidence-based biospecimen quality-control tools: A report of the International Society for Biological and Environmental Repositories (ISBER) Biospecimen Science Working Group. The Journal of Molecular Diagnostics 2012 Nov 26. [Epub 2012 Nov 26]
PubMed abstract
|
|
Bowles EJ, Wellman R, Fiegelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis R, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. Journal of the National Cancer Institute 2012 Sep 5;104(17):1293-305. PMCID:PMC3433392
Full text
|
|
Cross D, Rahm A, Le A, Webster J, Potosky A, Feigelson H, Alexander G, Pawolski P, Williams A, Daida Y, Honda S, Onitilo A, McCarty C, Goddard K.PS1-08: Lynch Syndrome screening patterns in colorectal cancer patients in a large multi-institutional cohort. Clinical Medical Research 2012 Aug; 10(3):146. PMC3421367
Full text
|
|
Delate T, Bowles EA, Pardee R, Wellman R, Habel L, Yood MU, Nekhlyudov L, Goddard, K, Davis R, McCarty C, Onitilo A, Feigelson HS, Freml J, Wagner E. Validity of eight integrated healthcare delivery organizations’ administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiology, Biomarkers & Prevention 2012 Apr;21(4):673-80. [Epub 2012 Feb 15] PMCID: PMC3319397 [Available on 2013/4/1]
Full text
|
|
Deverka PA, Schully SD, Ishibe N, Carlson JJ, Freedman A, Goddard KA, Khoury MJ, Ramsey SD. Stakeholder assessment of the evidence for cancer genomic tests: Insights from three case studies. Genet Med 2012 Jul;14(7):656-62.
PubMed abstract
|
|
El-Meanawy A, Schelling JR, Iyengar SK, Hayden P, Barathan S,
Goddard K, Pozuelo F, Elashi E, Nair V, Kretzler M, Sedor JR. Identification of nephropathy candidate genes by comparing sclerosis-prone and sclerosis-resistant mouse strain kidney transcriptomes. BMC Nephrology 2012 Jul 19;13(1):61. [Epub ahead of print] PMC3502501
Full text
|
|
Feigelson HS, Goddard KAB, Johnson MA, Funk KC, Rahm AK, Kauffman TL, Chitale DA, Le Marchand LL, Richards CS. Reliability of KRAS mutation testing in metastaticcolorectal cancer patients across five laboratories. BMC Research Notes 2012 2012 Apr 25; 5(1):196. PMCID: PMC3441241
Full text
|
|
Goddard KA, Aiello Bowles EJ, Spencer Feigelson H, Habel LA, Alford SH, McCarty CA, Nekhlyudov L, Onitilo AA, Rahm AK, Webster JA. Utilization of HER2 genetic testing in a multi-institutional observational study. American Journal of Managed Care 2012 Nov; 18(11):704-12. NIHMSID # 436570
Full text
|
|
Goddard KAB, Knaus WA, Whitlock EP, Lyman GH, Feigelson HS, Schully S, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL. Building the evidence base for decision making in cancer genomics using comparative effectiveness research. Genetics in Medicine 2012 Jul; 14(7):633-42. [Epub 2012 Apr 19]
Full text
|